ArticleMolecular and clinical oncology2019

Study on the infusion-site adverse events and vascular distribution of epirubicin in chemotherapy with epirubicin and fosaprepitant.

Miho Yamasaki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.